ProMab Biotechnologies Signs Worldwide License Agreement with NantKwest to Develop Ab for Multiple Myeloma

 ProMab Biotechnologies Signs Worldwide License Agreement with NantKwest to Develop Ab for Multiple Myeloma

ProMab Biotechnologies Signs Worldwide License Agreement with NantKwest to Develop Ab for Multiple Myeloma

Shots:

  • ProMab Biotechnologies signs WW license agreement with NantKwest to develop Ab targeting B-Cell Maturation Antigen (BCMA) against myeloma
  • ProMab Biotechnologies get an option to add five chimeric antigen receptor (CAR) targeting sequences based on natural killer (NK) cell therapies
  • NantKwest’s lead NK cell platform includes haNK and taNK designed to induce cell death by innate, antibody-mediated, and CAR directed killing against cancer and virally induced infectious diseases

Click here to read full press release/ article | Ref: Nantkwest | Image: Nantkwest

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post